Sugi Predict

Sugi Predict / Compounds / SCHEMBL1995808

SCHEMBL1995808

SCHEMBL1995808

CCOC(=O)c1ccc(NC(=O)CC(CNS(=O)(=O)c2ccc(Cc3ccccc3)cc2)c2ccc(Cl)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 2/20 0.50
▸ MAPT P10636 4/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ CA9 Q16790 2/20 0.48
▸ CA12 O43570 1/20 0.48
▸ PRMT1 Q99873 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ LMNA P02545 2/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ SGMS1 Q86VZ5 1/20 0.45
▸ FNTA P49354 2/20 0.45
▸ FNTB P49356 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12611461 0.90 FNTA (0.56) MAPTALDH1A1CA9CA12LMNA
SCHEMBL1996063 0.89 CA9 (0.56) TP53MAPTALDH1A1CA9CA12
SCHEMBL2002332 0.86 CA9 (0.58) TP53MAPTALDH1A1CA9CA12
SCHEMBL2000239 0.83 FNTA (0.54) MAPTALDH1A1CA9CA12LMNA
SCHEMBL1999366 0.82 LMNA (0.57) TP53MAPTALDH1A1LMNACYP2D6
SCHEMBL1998176 0.81 FNTA (0.55) TP53MAPTALDH1A1CA9CA12
SCHEMBL12617213 0.81 FNTA (0.58) TP53MAPTALDH1A1LMNACYP2D6
SCHEMBL2001883 0.80 FNTA (0.61) SGMS1FNTAFNTBMEN1KMT2A
SCHEMBL2000109 0.79 CA9 (0.52) TP53MAPTALDH1A1CA9CA12
SCHEMBL1996715 0.79 MEN1 (0.51) MAPTALDH1A1CA9CA12LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210121427-A1 SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY H LEE MOFFITT CANCER CT & RES (US) 2021-04-29 — — US disclosed
US-10806712-B2 Small molecule inhibitors of STAT3 with anti-tumor activity H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2020-10-20 — — US disclosed
US-20190192461-A1 SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY H LEE MOFFITT CANCER CT & RES (US) 2019-06-27 — — US disclosed
US-10226439-B2 Small molecule inhibitors of STAT3 with anti-tumor activity H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2019-03-12 — — US disclosed
US-20170202795-A1 SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY H LEE MOFFITT CANCER CT & RES (US) 2017-07-20 — — US disclosed
US-9604923-B2 Small molecule inhibitors of STAT3 with anti-tumor activity H.LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2017-03-28 — — US disclosed
US-20140329900-A1 SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2014-11-06 — — US disclosed
US-20110201576-A1 Small molecule inhibitors of stat3 with anti-tumor activity H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) 2011-08-18 — — US disclosed
US-7960434-B2 Small molecule inhibitors of STAT3 with anti-tumor activity UNIVERSITY OF SOUTH FLORIDA (US) 2011-06-14 — — US disclosed
US-20090069420-A1 Small molecule inhibitors of STAT3 with anti-tumor activity H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) 2009-03-12 — — US disclosed
WO-2007136858-A2 SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) 2007-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170202795-A1 SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY STAT3, STAT1, STAT5A TP53 26/4885MAPT 4441/4885ALDH1A1 3674/4885
US-20210121427-A1 SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY STAT3, STAT1, STAT5A TP53 26/4885MAPT 4441/4885ALDH1A1 3674/4885
US-20110201576-A1 Small molecule inhibitors of stat3 with anti-tumor activity STAT3, STAT1, STAT5A TP53 26/4885MAPT 4441/4885ALDH1A1 3674/4885
US-20090069420-A1 Small molecule inhibitors of STAT3 with anti-tumor activity STAT3, STAT1, STAT5A TP53 26/4885MAPT 4441/4885ALDH1A1 3674/4885
US-20140329900-A1 SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY STAT3, STAT1, JAK2 TP53 31/4885MAPT 4537/4885ALDH1A1 3626/4885
US-20190192461-A1 SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY STAT3, STAT1, STAT5A TP53 26/4885MAPT 4441/4885ALDH1A1 3674/4885
US-10226439-B2 Small molecule inhibitors of STAT3 with anti-tumor activity STAT3, STAT1, STAT5A TP53 26/4885MAPT 4441/4885ALDH1A1 3674/4885
US-10806712-B2 Small molecule inhibitors of STAT3 with anti-tumor activity STAT3, STAT1, STAT5A TP53 26/4885MAPT 4441/4885ALDH1A1 3674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.